Wednesday, February 10, 2016

Analyst: Something's got to give with AstraZeneca

Bernstein Research analyst Tim Anderson said in a note to clients that something has to give with AstraZeneca, which said Friday it got bad news on Seroquel generic competition..

Analyst: Something's got to give with AstraZeneca


Bernstein Research analyst Tim Anderson said in a note to clients that something has to give with AstraZeneca.

The English drugmaker, which has a big operation in Wilmington and Newark, Del., has struggled to deal with the common ailments of big pharma companies: loss of patent protection for top-selling drugs, pipelines not producing blockbuster replacements and pricing pressure from public and private insurers.

The company has cut jobs several times in the last two years.

The synopsis of Anderson's note is here and the "we" refers to Anderson and Bernstein Research:

• AstraZeneca is a consensus "sell" with the lowest valuation of the European Union/U.S. names we cover. This is because its future financial profile is troubling due to a long list of future patent expiries and also a thin pipeline. Something seems destined to change.

• Two very different strategies sit before the company. The first is for AstraZeneca to cut down its cost structure even more, but we think it is running out of room. The second is for AstraZeneca to start making acquisitions (which we think is the more likely option).

• We run merger and acquisition scenarios of three different sizes to assess their financial impact:

a) Buy Amylin for $4.5 billion.

b) Buy Shire, which has a big Philadelphia-area presence, for $30 billion.

c) Buy Abbott's drug business for $52 billion.

Anderson didn't say that would happen. He just ran numbers on the possibilities, but also suggested acquisitions under $10 billion are most likely.

Meanwhile, the patent problem was brought home Friday morning when AstraZeneca said in a statement on its website that the U.S. Food and Drug Administration had denied AstraZeneca's request to delay approval of generic competitors to its top-selling antipsychotic Seroquel over labeling issues.

Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Staff Writer
Also on
letter icon Newsletter